General Anesthesia Drugs Market
Description
General Anesthesia Drugs Market, By Drug molecule (Desflurane, Isoflurane, Sevoflurane, Propofol, Etomidate, Methohexital, hiopentone, Midazolam, Ketamine), By Route of Administration (Intravenous Anesthesia, Inhalation Anesthesia), By End User (Hospital, Specialty Clinics, Ambulatory Surgical Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
General anesthesia drugs are meant to manifest unconscious patient by the inhibition of sensory, motor, and sympathetic nerve transmission at the level of the brain that results in unconsciousness and lack of sensation and incapable to feel painful stimuli while controlling involuntary reflexes. General anesthesia drugs are administrated by two routes either by intravenous anesthetics that includes drug molecules like propofol, etomidate, methohexital, thiopentone, midazolam and ketamine and other is inhalation anesthetics that includes drug molecules like desflurane, isoflurane, and sevoflurane. The key players are primarily focusing on modifying the chemical structures of existing drugs or drug classes with a direction to improve their pharmacokinetic, pharmacodynamics, and side effect properties. Furthermore, they are developing drugs that have possibilities of using Target Controlled Infusion (TCI). The new applications of pre-existing anesthetic drugs are being explored. Thus, the introduction of such drugs with lesser side effects and target controlled infusion in the market are expected to drive the growth of the global general anesthesia drugs market over the forecast period.Market Dynamics
The key players in the pharmacology industry are focusing on the development of drugs with lesser side effects by the modification of preexisting drugs. For instance, in July 2022, Cosmo pharmaceuticals, a global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved BYFAVO (Remimazolam), a novel benzodiazepine for intravenous anesthetics approved for use as procedural sedation and general anesthesia. It has an ultra-short duration of action and it uses target controlled infusion with short and expected duration of sedative action, short recovery time, rare accumulation after long-term infusion, and lesser side effects as compared to those of other currently used Benzodiazepines molecule of general anesthesia drugs. Thus, the introduction of such drugs with lesser side effects in the market is expected offer opportunities for drug manufacturers to develop more novel drugs with lesser side effects.
Key features of the study:
- This report provides an in-depth analysis of the global general anesthetic drug market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year. It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global general anesthetic drug market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as a part of this study include Baxter Healthcare, Dr. Reddy's Laboratories, Fresenius Kabi, Pfizer Inc., Hikma Pharmaceuticals, Sagent Pharmaceuticals, Teva Pharmaceuticals, Par Pharmaceutical, Viatris Inc., AbbVie, Piramal Critical Care, Aspen Global Incorporated, B. Braun SE, Abbott, COSMO PHARMACEUTICALS, Hospira Inc., Maruishi, Hengrui, and Lunan
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global general anesthetic drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global general anesthetic drug market.
- Global General Anesthesia Drugs Market, By Drug molecule:
- Desflurane
- Isoflurane
- Sevoflurane
- Propofol
- Etomidate
- Methohexital
- Thiopentone
- Midazolam
- Ketamine
- Global General Anesthesia Drugs Market, By Route of Administration:
- Intravenous Anesthesia
- Inhalation Anesthesia
- Global General Anesthesia Drugs Market, By End User:
- Hospital
- Specialty Clinics
- Ambulatory Surgical Centers
- Global General Anesthesia Drugs Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Baxter Healthcare
- Dr. Reddy's Laboratories
- Novartis International AG
- Hospira
- Maruishi
- Hengrui
- Lunan
- Fresenius Kabi
- Pfizer Inc.
- Hikma Pharmaceuticals
- Sagent Pharmaceuticals
- Teva Pharmaceuticals
- Par Pharmaceutical
- Viatris Inc.
- AbbVie
- Piramal Critical Care
- Aspen Global Incorporated
- B. Braun SE
- Abbott
- Cosmo pharmaceuticals
Table of Contents
200 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
